InvestorsHub Logo
Followers 36
Posts 1166
Boards Moderated 0
Alias Born 03/07/2013

Re: gotinearly post# 176

Wednesday, 04/27/2016 10:42:05 PM

Wednesday, April 27, 2016 10:42:05 PM

Post# of 3630
Thanks for the post. Very sad to see that she is no longer on board.

Yes, she and her brother signed over their main life's research to RGBP under a 3 year contract and her milestone shares were to fully invest in June 2016.

The fact that she and her brother are no longer with RGBP and no longer attached to their life's passion and research smells to me. The PR claiming T. Ichim left for health reasons and the company's silence on C. Ichim no longer there when last year she was the star of the show is not a good sign no matter how you slice it. Did they leave of their own accord? Highly doubtful. Did Koos find a way/means to get rid of them as he did Christopher Mizer a couple years back, more likely.

I don't have a good feeling about this at all and I think Koos is behind it in a non positive way. To me this is a blow even if the science goes forward. Not a positive development in my view.

And others will question. How does this affect Kesari who is now main researcher for NR2F6 and dCellVax and maybe tCellVax. I think he and C. Ichim were involved in the same institute. If he and other collaborators see a fellow research scientist treated unfairly, it most likely will have a negative impact on the future relationship of other current collaborators.